The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
The majority of malignancies displayed moderate to strong nuclear immunoreactivity, often accompanied by weaker cytoplasmic staining. Most skin, testicular and gastric cancers along with the majority of malignant melanomas, ovarian, endometrial and urothelial cancers were weakly stained or negative.
Most malignancies exhibited moderate to strong nuclear immunoreactivity. Several basal cell carcinomas, melanomas and endometrial cancers were either negative or weakly stained.
Most malignant cells displayed moderate to strong nuclear positivity with additional cytoplasmic staining in several cases. Several cases of stomach cancers, basal cell carcinomas and malignant melanomas were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
